[
    [
        {
            "time": "",
            "original_text": "【医药公司专题分析之年报系列(1)】津同仁堂(834915)新三板策略事件点评：核心药品增长稳健 积极拓展新老产品",
            "features": {
                "keywords": [
                    "医药公司",
                    "津同仁堂",
                    "新三板",
                    "核心药品",
                    "增长稳健",
                    "积极拓展",
                    "新老产品"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【医药公司专题分析之年报系列(1)】津同仁堂(834915)新三板策略事件点评：核心药品增长稳健 积极拓展新老产品",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]